# Role of Anti-Inflammatory Agents in Patients With Schizophrenia

> **NCT00929955** · PHASE1 · COMPLETED · sponsor: **Pakistan Institute of Living and Learning** · enrollment: 36 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder
- Psychosis Not Otherwise Specified
- Schizophreniform Disorder

## Interventions

- **DRUG:** Ondansetron
- **DRUG:** Simvastatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00929955
- **Lead sponsor:** Pakistan Institute of Living and Learning
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-09
- **Final completion:** 2010-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-08-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00929955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00929955, "Role of Anti-Inflammatory Agents in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00929955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*